PT Murni Sadar Tbk, (MTMH) Fair Value & Analysis
Healthcare · ID · Market cap 2.0T IDR
Fair value as of: Jul 17, 2026
From 14 valuation models · updated 24 days ago
Share price −3.1% over the past month.
Below-average quality, and screening another 50% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (579.96 IDR). The favourable scenario is already priced in.
- Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
52‑month range 837.99 IDR – 2,723 IDR · fair‑value band 347.98 IDR – 579.96 IDR · the 935.00 IDR price screens above the 463.97 IDR fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
PT Murni Sadar Tbk, (MTMH) currently trades at 935.00 IDR, while our model-based Fair Value estimate is 463.97 IDR, implying the stock looks roughly 50.4% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, PT Murni Sadar Tbk, generated revenue of 1.4T IDR at a net margin of 2.9%. Revenue grew 22.9% year over year. It earns a return on equity of 2.7%. Net debt stands at 747B IDR. Fundamentals as of Jul 17, 2026
Our scenario range runs from 347.98 IDR (bear case) to 579.96 IDR (bull case); at 935.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -50%, MTMH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (558.78 IDR) versus Economic Profit (288.11 IDR). Highest evidence: ROIC Compounder (72).
Notify me when MTMH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Murni Sadar Tbk, together with its subsidiaries, provides health services and manages private hospitals in Indonesia.
Full company description
PT Murni Sadar Tbk, together with its subsidiaries, provides health services and manages private hospitals in Indonesia. The company offers outpatient installation services, including specialist, family health, general, dental, tropical diseases, travel medicine, and pain clinics; laboratory services, such as clinical pathology, blood bank, biomolecular/PCR, microbiology, and anatomical pathology; radiotherapy, consists of LINAC, CT-simulator and immobilization, treatment planning system, and brachytherapy services. It also provides radiology services, including general X-Ray, ultrasonography (USG), mammography, 128 slice CT scan, 1.5 Tesla MRI, and interventional radiology; heart & vascular center, such as ECG, treadmill test, echocardiology, holter monitoring, and cardiac catheterization laboratory; endoscopy, contain esophagoscopy, gastroscopy, colonoscopy, bronchoscopy, and ERCP; medical rehabilitation, comprising physiotherapy, speech and occupation therapy, and orthotic prosthetic. In addition, the company offers general services, which includes emergency installation, and inpatient facility; intensive care; public facilities; operating theatres, ESWL, laporoscopic surgery, oncology, chemotherapy, pharmaceutical installations, medical checkup, lifestyle clinic, murni teguh IVF, home care, palliative care, EEG, EMG, and ambulance services; as well as operates IVF Centre. Further, it provides general facilities such as, auditorium, cafeteria, commercials area, fitness gym, and homestay. PT Murni Sadar Tbk was founded in 2010 and is based in Medan, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Murni Sadar Tbk, reported revenue of 1.4T IDR in FY2025 versus 983B IDR in FY2021, a compound +8.4%/yr. Reported net income was 43.6B IDR in FY2025, compounding −23.9%/yr from FY2021.
MTMH screens 50% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Murni Sadar Tbk, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Murni Sadar Tbk, (MTMH) overvalued or undervalued?
What is the fair value of MTMH?
What is the quality score of MTMH?
What is the revenue of PT Murni Sadar Tbk, (MTMH)?
What is the net profit margin of MTMH?
Does PT Murni Sadar Tbk, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Murni Sadar Tbk, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.